Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia.

Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia Since the introduction of the automated fluorogenic thrombin generation (TG) assay in early 2000, many attempts have been made to apply it to characterize the phenotypes of haemophilic patients and monitor the treatment and prevention of bleeding episodes. GLO:EVW/01jan21:hae14024-fig-0002.jpg PHOTO (COLOR): 2 Pathways of the coagulation cascade involved in the generation of thrombin signal in variously triggered thrombin generation assay (TG assay). The second I Haemophilia i paper compared the TG assays triggered with FIXa and FXIa in the absence of TF3 reporting higher inter-assay variability (up to 25%) in FXIa-triggered TG assay, and suggested that FIXa-triggered TG assay should be chosen for better robustness. [Extracted from the article]